Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study.

Conclusions: Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional large-scale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed.
PMID: 29172402 [PubMed - as supplied by publisher]

Source: The Korean Journal of Internal Medicine - November 27, 2017 Category: Internal Medicine Authors: You SC, Park H, Yoon D, Park S, Joung B, Park RW Tags: Korean J Intern Med Source Type: research